NAM
MIRM icon

Nexpoint Asset Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Nexpoint Asset Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,000
Closed -$101K – 333
2019
Q3 		$101K Buy
+10,000
New +$123K 0.01% 312

Other funds holding MIRM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Nexpoint Asset Management's MIRM Position: Q4 2019 in Review

Nexpoint Asset Management sold out of Mirum Pharmaceuticals (MIRM) in Q4 2019, closing a stake of 10,000 shares — an estimated $101K sold.

Nexpoint Asset Management first reported a position in MIRM in Q3 2019 and held it in 1 quarter. The position peaked at $101K in Q3 2019. 39 funds tracked by Wall St. Rank hold MIRM as of Q4 2019.

  • Nexpoint Asset Management reported no remaining Mirum Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Nexpoint Asset Management sold 10,000 Mirum Pharmaceuticals shares in Q4 2019, an estimated $101K.
  • Nexpoint Asset Management first reported a position in Mirum Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Nexpoint Asset Management's Mirum Pharmaceuticals position peaked at $101K in Q3 2019.
  • 39 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2019.

Based on Nexpoint Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.